We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Pregnancy Test Tells When Conception Occurred

By LabMedica International staff writers
Posted on 29 Sep 2008
A one-step rapid pregnancy test also indicates an approximate date of conception.

The test is very simple and accurate. More...
Urine is applied to an absorbent sampler activating the test, which automatically calibrates itself. A "Wait” symbol on the liquid crystal display (LCD) display screen indicates the test is working. Within three minutes, an easy to read result is displayed. If the test is positive, "Pregnant” will be indicated in words on the display along with the Conception Indicator result. This is displayed as an estimate of how many weeks have occurred since conception: 1-2 weeks, 2-3 weeks or 3+ weeks.

Once a fertilized egg implants in the uterus wall, a woman's body produces the pregnancy hormone, human chorionic gonadotropin (hCG). This rapidly increases during the early weeks of pregnancy and is present in urine. It is this hormone that pregnancy tests detect when confirming a positive result. Clearblue (Waltham, MA, USA) launched the Clearblue digital pregnancy test with Conception Indicator--the only pregnancy test that is so advanced it is capable of telling a woman both if she is pregnant, and provide an indication when she might have conceived.

In laboratory tests, Clearblue digital pregnancy test is more than 99% accurate in detecting pregnancy, when used from the day the period is due. The Conception Indicator result is 92% accurate at indicating when a woman conceived, and when using the first urine of the day. As with the original Clearblue digital pregnancy test, the Conception Indicator is a one-step rapid test designed to be used once before disposal.

Clearblue launched the new test following extensive clinical studies to pinpoint the different levels of hCG required to estimate when conception occurred. Dr. Jayne Ellis, director of new product development at Clearblue commented, "The Conception Indicator is something we have been researching for a number of years, and the final product is unique. We are excited to be able to offer women more valuable information about their pregnancy as soon as the "pregnant” result is confirmed.”

Related Links:
Clearblue



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.